Molecular genetics and the assessment of human cancers

Expert Reviews in Molecular Medicine

Volumn 1, Issue 8, 1999, Pages 1-19

  Caldas, Carlos ^a   Pharoah, Paul D P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

cancer; diagnostic; FISH; LOH; loss of imprinting; microsatellite instability; molecular genetics; neoplasia; oncogene; tumor suppressor; tumour suppressor

Indexed keywords

EID: 85012501601     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399499000526     Document Type: Article

References (115)

1. Boyle, P. (1997) Global burden of cancer. Lancet 349 Suppl 2, SII23–26, PubMed ID:97307231
2. Sidransky, D. (1997) Nucleic acid-based methods for the detection of cancer. Science 278, 1054–1059, PubMed ID:98016269
3. Nowell, P.C. (1976) The clonal evolution of tumor cell populations. Science 194, 23–28, PubMed ID:76271151
4. Kinzler, K.W. and Vogelstein, B. (1996) Lessons from hereditary colorectal cancer. Cell 87, 159–170, PubMed ID:97015071
5. Laird, P.W. (1997) Oncogenic mechanisms mediated by DNA methylation. Mol Med Today 3, 223–229, PubMed ID:97320001
6. Feinberg, K.W. (1998) Genomic Imprinting and Cancer. In The Genetic Basis of Human Cancer (Vogelstein, B. and Kinzler, K.W., eds), pp. 95–108, McGraw-Hill, New York
7. Arzimanoglou, II, Gilbert, F. and Barber, H.R. (1998) Microsatellite instability in human solid tumors. Cancer 82, 1808–1820, PubMed ID:98246539
8. Mao, L. et al. (1994) Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci U S A 91, 9871–9875, PubMed ID:95024063
9. Lengauer, C., Kinzler, K.W. and Vogelstein, B. (1997) Genetic instability in colorectal cancers. Nature 386, 623–627, PubMed ID:97256539
10. Zhang, L. et al. (1997) Gene expression profiles in normal and cancer cells. Science 276, 1268–1272, PubMed ID:97301861
11. Zhou, W. et al. (1998) Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev 7, 109–112, PubMed ID:98147908
12. Sidransky, D. et al. (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252, 706–709, PubMed ID:91220071
13. Hruban, R.H. et al. (1994) Brief report: molecular biology and the early detection of carcinoma of the bladder-the case of Hubert H. Humphrey. N Engl J Med 330, 1276–1278, PubMed ID:94195346
14. Wakabayashi, T. et al. (1996) Detection of K-ras point mutation at codon 12 in pure pancreatic juice collected 3 years and 6 months before the clinical diagnosis of pancreatic cancer. Am J Gastroenterol 91, 1848–1851, PubMed ID:96384853
15. Mao, L. et al. (1994) Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 54, 1634–1637, PubMed ID:94184990
16. Bos, J.L. et al. (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293–297, PubMed ID:87229009
17. Hollstein, M. et al. (1991) p53 mutations in human cancers. Science 253, 49–53, PubMed ID:91289156
18. Potter, M.A. et al. (1998) Detection of mutations associated with colorectal cancer in DNA from whole-gut lavage fluid. J Natl Cancer Inst 90, 623–626, PubMed ID:98213109
19. Mao, L. et al. (1996) Molecular detection of primary bladder cancer by microsatellite analysis. Science 271, 659–662, PubMed ID:96165395
20. Caldas, C. et al. (1994) Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 54, 3568–3573, PubMed ID:94282773
21. Yanagisawa, A. et al. (1993) Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 53, 953–956, PubMed ID:93177709
22. Rivera, J.A. et al. (1997) Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. Surgery 121, 42–49, PubMed ID:97154836
23. Brennan, J.A. et al. (1995) Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332, 429–435, PubMed ID:95124432
24. Hayashi, N. et al. (1994) Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res 54, 3853–3856, PubMed ID:94306395
25. Hayashi, N. et al. (1995) Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 345, 1257–1259, PubMed ID:95264815
26. Hardingham, J.E. et al. (1995) Detection of circulating tumor cells in colorectal cancer by immunobead- PCR is a sensitive prognostic marker for relapse of disease. Mol Med 1, 789–794, PubMed ID:96192947
27. Hibi, K. et al. (1998) Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 58, 1405–1407, PubMed ID:98196530
28. de Kok, J.B. et al. (1997) Detection of tumour DNA in serum of colorectal cancer patients. Scand J Clin Lab Invest 57, 601–604, PubMed ID:98059880
29. Kopreski, M.S. et al. (1997) Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer 76, 1293–1299, PubMed ID:98040530
30. Chen, X.Q. et al. (1996) Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 2, 1033–1035, PubMed ID:96376356
31. Nawroz, H. et al. (1996) Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 2, 1035–1037, PubMed ID:96376357
32. Yamada, T. et al. (1998) Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 4, 1527–1532, PubMed ID:98289775
33. Pack, S. et al. (1997) Detection of gene deletion in single metastatic tumour cells in lymphnode tissue by fluorescent in-situ hybridisation [letter]. Lancet 350, 264–265, PubMed ID:97386719
34. Pack, S.D. et al. (1998) Detection of gene deletion in single metastatic tumor cells in the excision margin of a primary cutaneous melanoma [letter]. J Natl Cancer Inst 90, 782–783, PubMed ID:98266687
35. Slamon, D.J. et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182, PubMed ID:87094192
36. Thor, A.D. et al. (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90, 1346–1360, PubMed ID:98418638
37. Paik, S. et al. (1998) erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90, 1361–1370, PubMed ID:98418639
38. Bergh, J. et al. (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1, 1029–1034, PubMed ID:96071632
39. Jansson, T. et al. (1995) p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 13, 2745–2751, PubMed ID:96067232
40. Aas, T. et al. (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2, 811–814, PubMed ID:96266335
41. Jacquemier, J. et al. (1995) Histoprognostic grade in BRCA1-associated breast cancer [letter]. Lancet 345, 1503, PubMed ID:95287719
42. Eisinger, F. et al. (1996) Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56, 471–474, PubMed ID:96147253
43. Sobol, H. et al. (1996) Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. Cancer Res 56, 3216–3219, PubMed ID:96320460
44. Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349, 1505–1510, PubMed ID:97310292
45. Watson, P., Marcus, J.N. and Lynch, H.T. (1998) Prognosis of BRCA1 hereditary breast cancer. Lancet 351, 304–305, PubMed ID:98314712
46. Verhoog, L.C. et al. (1998) Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351, 316–321, PubMed ID:98314719
47. Ansquer, Y. et al. (1998) Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group [letter]. Lancet 352, 541, PubMed ID:98379917
48. Takanishi, D.M., Jr. et al. (1995) Chromosome 17p allelic loss in colorectal carcinoma. Clinical significance. Arch Surg 130, 585–588
49. discussion 588–589, PubMed ID:95283445
50. Kern, S.E. et al. (1989) Clinical and pathological associations with allelic loss in colorectal carcinoma [published erratum appears in JAMA 1989 Oct 13;262(14):1952]. JAMA 261, 3099–3103, PubMed ID:89236567
51. Kato, M. et al. (1996) Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. Cancer 77, 1729–1735, PubMed ID:96197488
52. Hamelin, R. et al. (1994) Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106, 42–48, PubMed ID:94102504
53. Carethers, J.M. et al. (1998) Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 114, 1188–1195, PubMed ID:98282356
54. Jen, J. et al. (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331, 213–221, PubMed ID:94285962
55. Martinez-Lopez, E. et al. (1998) Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 114, 1180–1187, PubMed ID:98282355
56. Ogunbiyi, O.A. et al. (1998) Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16, 427–433, PubMed ID:98129227
57. Ogunbiyi, O.A. et al. (1997) Prognostic value of chromosome 1p allelic loss in colon cancer. Gastroenterology 113, 761–766, PubMed ID:97434080
58. Goh, H.S., Yao, J. and Smith, D.R. (1995) p53 point mutation and survival in colorectal cancer patients. Cancer Res 55, 5217–5221, PubMed ID:96062171
59. Borresen-Dale, A.L. et al. (1998) TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4, 203–210, PubMed ID:98177616
60. Benhattar, J. et al. (1993) Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 104, 1044–1048, PubMed ID:93216013
61. Tanaka, M. et al. (1994) Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol 57, 57–64, PubMed ID:94343855
62. Andersen, S.N. et al. (1997) K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol 32, 62–69, PubMed ID:97171551
63. Lee, J.C. et al. (1996) K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 16, 3839–3844, PubMed ID:97194829
64. Ahnen, D.J. et al. (1998) Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58, 1149–1158, PubMed ID:98175552
65. Senagore, A.J. and Biener, J.T. (1997) A newly identified pattern of K-ras mutations at codons 12 and 13 is associated with long-term survival in colorectal cancer. Surgery 122, 765–770, PubMed ID:98007544
66. Nakamori, S. et al. (1995) Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 86, 174–181, PubMed ID:95247542
67. Sheridan, E. et al. (1994) P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. Eur J Cancer 11, 1701–1704, PubMed ID:95134542
68. Kelker, W. et al. (1996) Loss of 18q and homozygosity for the DCC locus: possible markers for clinically aggressive squamous cell carcinoma. Anticancer Res 16, 2365–2372, PubMed ID:96413682
69. Rasheed, B.K. et al. (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54, 1324–1330, PubMed ID:94163627
70. Baxendine-Jones, J., Campbell, I. and Ellison, D. (1997) p53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol 16, 332–336, PubMed ID:98065333
71. Tada, M. et al. (1998) Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res 58, 1793–1797, PubMed ID:98240970
72. Rubin, S.C. et al. (1996) Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335, 1413–1416, PubMed ID:97029994
73. Johannsson, O.T. et al. (1998) Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16, 397–404, PubMed ID:98129223
74. Hartmann, A. et al. (1997) The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 13, 27–33, PubMed ID:97162998
75. Miyoshi, Y. et al. (1992) Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1, 229–233, PubMed ID:93265030
76. Powell, S.M. et al. (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359, 235–237, PubMed ID:92408778
77. Salgia, R. and Skarin, A.T. (1998) Molecular abnormalities in lung cancer. J Clin Oncol 16, 1207–1217, PubMed ID:98167634
78. Hahn, S.A. and Kern, S.E. (1995) Molecular genetics of exocrine pancreatic neoplasms. Surg Clin North Am 75, 857–869, PubMed ID:95389296
79. Goggins, M. et al. (1998) Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 152, 1501–1507, PubMed ID:98289294
80. Hahn, S.A. et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350–353, PubMed ID:96144684
81. Caldas, C. et al. (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma [published erratum appears in Nat Genet 1994 Dec;8(4):410]. Nat Genet 8, 27–32, PubMed ID:95078918
82. Sidransky, D. et al. (1992) Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256, 102–105, PubMed ID:92229409
83. Hasegawa, Y. et al. (1995) Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). Oncogene 10, 1441–1445, PubMed ID:95249255
84. Smith-Ravin, J. et al. (1995) Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. Gut 36, 81–86, PubMed ID:95197084
85. Villa, E. et al. (1996) Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 110, 1346–1353, PubMed ID:96200518
86. Minamoto, T. et al. (1995) Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis. Cancer 75, 1520–1526, PubMed ID:95196176
87. Tobi, M., Luo, F.C. and Ronai, Z. (1994) Detection of K-ras mutation in colonic effluent samples from patients without evidence of colorectal carcinoma. J Natl Cancer Inst 86, 1007–1010, PubMed ID:94275886
88. Spafford, M.F. et al. (1998) Detection of head and neck squamous cell carcinoma in saliva using microsatellite analysis. Proceedings of the American Association for Cancer Research, 39, 100
89. Boyle, J.O. et al. (1994) Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg 168, 429–432, PubMed ID:95068609
90. Mills, N.E. et al. (1995) Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis [published erratum appears in J Natl Cancer Inst 1995 Nov 1;87(21):1643]. J Natl Cancer Inst 87, 1056–1060, PubMed ID:95341709
91. Wilentz, R.E. et al. (1998) K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 82, 96–103, PubMed ID:98088760
92. Shibata, D. et al. (1990) Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res 50, 1279–1283, PubMed ID:90124343
93. van Es, J.M. et al. (1995) Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product. J Clin Pathol 48, 218–222, PubMed ID:95247920
94. Evans, D.B. et al. (1996) Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique. Ann Surg Oncol 3, 241–246, PubMed ID:96292642
95. Villanueva, A. et al. (1996) Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses. Gastroenterology 110, 1587–1594, PubMed ID:96200546
96. Yamashita, K. et al. (1998) Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination. Am J Clin Pathol 109, 704–711, PubMed ID:98281326
97. Uehara, H. et al. (1996) Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice. Am J Gastroenterol 91, 1616–1621, PubMed ID:96322182
98. Miki, H. et al. (1993) Detection of c-Ki-ras point mutation from pancreatic juice. A useful diagnostic approach for pancreatic carcinoma. Int J Pancreatol 14, 145–148, PubMed ID:94110670
99. Watanabe, H. et al. (1996) Detection of K-ras point mutations at codon 12 in pure pancreatic juice for the diagnosis of pancreatic cancer by PCR-RFLP analysis. Pancreas 12, 18–24, PubMed ID:96402901
100. Berthelemy, P. et al. (1995) Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 123, 188–191, PubMed ID:95321512
101. Apple, S.K. et al. (1996) Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears. Am J Clin Pathol 105, 321–326, PubMed ID:96180965
102. Abbruzzese, J.L. et al. (1997) Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer. Anticancer Res 17, 795–801, PubMed ID:97283277
103. Andersen, T.I. et al. (1993) Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68, 540–548, PubMed ID:93357150
104. Berns, E.M. et al. (1998) Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer 77, 1130–1136, PubMed ID:98228005
105. Caleffi, M. et al. (1994) p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer 73, 2147–2156, PubMed ID:94207975
106. Elledge, R.M. et al. (1993) Prognostic significance of p53 gene alterations in node-negative breast cancer. Int J Cancer 74, 642–647, PubMed ID:98081716
107. Falette, N. et al. (1998) Prognostic value of P53 gene mutations in a large series of node- negative breast cancer patients. Cancer Res 58, 1451–1455, PubMed ID:98196537
108. Iacopetta, B. et al. (1998) Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res 4, 1597–1602, PubMed ID:98339454
109. Kovach, J.S. et al. (1996) Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci U S A 93, 1093–1096, PubMed ID:96165524
110. Riou, G. et al. (1993) Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst 85, 1765–1767, PubMed ID:94016684
111. Saitoh, S. et al. (1994) p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene 9, 2869–2875, PubMed ID:94366733
112. Seshadri, R. et al. (1996) Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis [published erratum appears in Int J Cancer 1996 Aug 22;69(4):354]. Int J Cancer 69, 135–141, PubMed ID:96201724
113. Shiao, Y.H. et al. (1995) Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res 55, 1485–1490, PubMed ID:95188196
114. Soong, R. et al. (1997) Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Breast Cancer Res Treat 26, 225–235, PubMed ID:94072743
115. Thorlacius, S. et al. (1995) TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 31A, 1856–1861, PubMed ID:96138109